Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Category list : All-Wales Medicines Strategy Group

Sort by: Newest first Oldest first A-Z Z-A

  • Carwyn Jones, First Minister of the National Welsh Assembly

    Welsh Labour pledge to create £80m central fund for high cost drugs Subscription

    15 APR 2016 10:11

    Welsh Labour has pledged to create an £80m central fund to pay for high cost medicines if they retain control of the National Assembly for Wales following the election on 5 May 2016.

  • The Welsh Government office at Llandudno Junction

    Welsh audit body recommends managing medicines plan

    22 DEC 2016 9:10 By Gareth Malson

    The government, the NHS and health bodies should revise the indicators used to compare how different prescribers and organisations use medicines, says a report by the Welsh Audit Office.

  • vaughan gething wales welsh wales health secretary

    Treatment fund launched in Wales for newly approved drugs

    11 JAN 2017 17:31 By Debbie Andalo

    An £80m new treatment fund to pay for high-cost drugs approved for use on the NHS in Wales has been launched.

  • Pre-exposure prophylaxis pills against HIV infection

    Three-year PrEP pilot begins in Wales

    17 JUL 2017 15:44

    A trial has begun in Wales to assess the use of the antiretroviral combination treatment emtricitabine/tenofovir disoproxil (marketed as Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection.

  • Revlar Ellipta approved for NHS use in Wales

    29 MAY 2014 15:16

    Inhaled fluticasone furoate and vilanterol (Relvar Ellipta) has been approved for use in NHS Wales by the All-Wales Medicines Strategy Group (AWMSG). it is recommended as an option for symptomatic treatment of adults with chronic obstructive pulmonary disease.

  • The National Assembly for Wales building

    Restrictions on prescribing OTC treatments rejected in Wales Subscription

    24 APR 2019 14:16 By Corrinne Burns

    Proposals to restrict the prescribing of medicines and other treatments that are available over the counter will not go ahead in Wales.

  • Lubiprostone

    New constipation drug gets a lukewarm response from DTB

    11 APR 2014 10:34

    Little published data on lubiprostone made it difficult to assess its efficacy, says the DTB

  • June 2015 AWMSG approvals Subscription

    15 JUN 2015 14:54

    Adalimumab (Humira; AbbVie) can be prescribed in NHS Wales to treat active, enthesitis-related arthritis in patients aged six years and older, following its use being approved by the All Wales Medicines Strategy Group (AWMSG). The group has not recommended dapagliflozin (Forxgia; Bristol-Myers Squibb) as monotherapy for type 2 diabetes or aflibercept (Zaltrap; Sanofi) for metastatic colorectal cancer (in combination with irinotecan, ...

  • July 2015: AWMSG approvals Subscription

    10 JUL 2015 13:04

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstructive pulmonary disease, and Adcetris (brentuximab; Takeda) for adults with relapsed or refractory CD30+ Hodgkin lymphoma who have undergone an autologous stem cell transplant or following at least two other therapies. The drug is not recommended for treating systemic anaplastic large cell ...

  • January 2016: AWMSG approvals Subscription

    18 JAN 2016 13:51

    The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.